Rybelsus, Other Treatment Improvements For Chronic Disease Have OptumRx’s Attention

UnitedHealthcare’s pharmacy benefit manager highlights potential cost pressures from upcoming novel or improved treatments for diabetes, wet AMD, HIV and migraine, as well as luspatercept for beta thalassemia, in its latest pipeline report.

Businessman with binoculars. - Image
Horizon Scanning At OptumRx

[UnitedHealthCare]’s pharmacy benefit manager OptumRx Inc. flags Novo Nordisk AS’s just-approved oral semaglutide for type 2 diabetes, Rybelsus, and a handful of other novel or improved treatments for chronic conditions as near-term launches with potentially significant economic impacts in its latest Pipeline Insights Report.

The Q3 report, which is the second to be issued by the major PBM, offers a snapshot of potentially high-cost...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip